Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...
In patients with autoimmune hemolytic anemia (AIHA), the risk of relapse is high owing to persistent autoreactive B-cell activity. Multirefractory AIHA is a more advanced stage of disease that is ...
A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved CAR-T cell therapies offers long-term survival and potential cures for adult ...
HLA sensitization poses a major challenge to kidney transplantation for patients with end-stage kidney disease, especially for highly sensitized candidates. Attempts at antibody elimination ...
CAR-T therapy has transformed treatment for some blood cancers, with seven FDA-approved products and strong clinical responses in hematologic malignancies. However, its limitations remain evident. In ...
UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block ...
Early experience with T-cell receptor cellular therapy in advanced solid malignancies: A multi-center analysis of safety and efficacy. This is an ASCO Meeting Abstract from the 2026 ASCO Annual ...
Please provide your email address to receive an email when new articles are posted on . CAR T-cell therapy for cancer may be associated with new-onset autoimmune disease. Autoimmune events in after ...
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Researchers led by Universitätsmedizin Frankfurt and Goethe University Frankfurt have identified how particularly aggressive forms of lymphoma can be recognized.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results